Fintop1%

Fintop is a topical antifungal indicated for the treatment of certain superficial fungal skin infections. Evidence-based uses include:

• Established/approved uses: Interdigital tinea pedis (athlete's foot), tinea corporis (ringworm), and tinea cruris (jock itch) caused by susceptible dermatophytes such as Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.
• Established/approved use (yeast infection): Tinea (pityriasis) versicolor caused by Malassezia furfur.

Fintop is intended only for the fungal skin infections listed above; it is not effective against bacterial, viral, or nail (onychomycosis) infections, and it is not a systemic antifungal.

Each gram of topical cream typically contains Butenafine Hydrochloride 10 mg (1% w/w) in a water-miscible cream base. Local marketed strengths and pack sizes may vary; check the product label for the exact formulation dispensed.

Fintop is a synthetic benzylamine derivative with potent antifungal activity against dermatophytes. It is chemically distinct from, but pharmacologically related to, the allylamine class of antifungals (e.g., terbinafine, naftifine). It is formulated as a topical cream for external application to the skin only.

Topical antifungal agent (benzylamine derivative) — Fintop

Mechanism of Action

Butenafine Hydrochloride inhibits the fungal enzyme squalene epoxidase, blocking the conversion of squalene to lanosterol. This interrupts biosynthesis of ergosterol, an essential component of the fungal cell membrane, leading to membrane disruption and fungal cell death. Depending on the organism and concentration, Butenafine Hydrochloride may be fungicidal (against dermatophytes) or fungistatic.

Pharmacokinetics

Following topical application, systemic absorption of Butenafine Hydrochloride is minimal. Small amounts that are absorbed are metabolized in the liver and excreted mainly in urine and feces; clinically significant systemic exposure is not expected with normal topical use.

For external (topical) use only.

• Wash and thoroughly dry the affected area before applying Fintop.
• Apply a thin layer to cover the affected skin and the immediately surrounding area; gently rub in.
• Wash hands after application unless the hands are the area being treated.
• Avoid contact with the eyes, mouth, nose, and other mucous membranes; do not use intravaginally.
• Do not cover the treated area with occlusive dressings unless directed by a physician.
• Use consistently for the full recommended duration, even if symptoms improve earlier.

Because Fintop is applied topically and systemic absorption is minimal, clinically significant drug-drug interactions have not been well established. No formal interaction studies have identified clinically important systemic interactions.

As a general precaution, avoid simultaneous application of other topical products (including other antifungals, corticosteroids, or irritant cosmetics) to the same skin area unless advised by a physician, as this may alter local irritation or absorption.

Fintop is generally well tolerated. Reported adverse effects are usually mild and limited to the application site and include:

• Burning or stinging sensation
• Itching (pruritus)
• Redness (erythema) or irritation
• Contact dermatitis or rash (uncommon)
• Dryness or peeling of the skin

Severe allergic reactions are rare (see Contraindications). Persistent or worsening irritation should prompt discontinuation and medical review.

Pregnancy: Systemic absorption of Fintop after topical use is minimal; however, adequate, well-controlled studies in pregnant women are limited. Fintop should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Consult a physician before use.

Lactation: It is not known whether topically applied Fintop is excreted in human milk in clinically significant amounts. Caution is advised; avoid applying Fintop directly to the breast/nipple area if breastfeeding, and consult a physician before use during lactation.

• Fintop is for external/topical use only; avoid contact with the eyes, mouth, and other mucous membranes, and avoid intravaginal use unless a product is specifically labeled for that route.
• Local irritation, burning, or stinging may occur; discontinue and consult a physician if irritation is severe or persistent.
• Complete the full recommended treatment course even if symptoms improve earlier, as Fintop regimens (while often shorter than some other topical antifungals) still require full completion to reduce the risk of recurrence.
• If there is no improvement after the labeled treatment duration, or if symptoms worsen, stop use and seek medical evaluation to confirm the diagnosis or consider alternative therapy.
• Not intended for infections of the nails or scalp, or for suspected fungal infections in immunocompromised patients, without physician supervision.

Topical overdose with Fintop is unlikely to cause systemic toxicity given minimal skin absorption. Excessive application may increase the risk of local irritation, redness, or dermatitis at the application site; if this occurs, wash the area and discontinue use.

If Fintop cream is accidentally ingested or a significant amount is applied and systemic symptoms are suspected, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep the tube tightly closed and out of the reach of children.

Pregnant women: Use Fintop only if clearly needed; consult a physician (see Pregnancy and Lactation).

Breastfeeding women: Use with caution and physician guidance; avoid application to the breast area (see Pregnancy and Lactation).

Pediatric patients: Safety and efficacy established for children 12 years of age and older at the same dose as adults; not established in children under 12 years.

Elderly patients: No specific dose adjustment is required; general precautions for topical antifungal use apply.

Hepatic/renal impairment: Because systemic absorption is minimal after topical use, no dose adjustment is generally required; formal studies in these populations are limited.

Duration of Fintop therapy depends on the indication: typically 2 weeks for tinea corporis and tinea cruris, up to 4 weeks for interdigital tinea pedis (or 1 week with a twice-daily OTC regimen), and 2 weeks for tinea versicolor. The full course should be completed even if symptoms resolve early; if no improvement occurs within the labeled duration, medical review is advised.

Benzylamine antifungal (topical) — Butenafine Hydrochloride

Butenafine Hydrochloride inhibits fungal squalene epoxidase, preventing conversion of squalene to ergosterol precursors, thereby disrupting fungal cell membrane synthesis and producing fungicidal activity against dermatophytes.

B

Fintop cream is approved for use in adults and children 12 years of age and older for the labeled indications (tinea corporis, tinea cruris, interdigital tinea pedis, and tinea versicolor), using the same dose and duration as adults. Safety and efficacy of Fintop in children under 12 years of age have not been established, and use in this age group should only occur under medical supervision if considered necessary.